LUND, Sweden, Sept. 10, 2013 /PRNewswire/ -- BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced that data from a pivotal animal study of CERAMENT™|BONE VOID FILLER, were published online in the Journal of Orthopaedic Surgery and Research. The aim of the study was to compare the stability of non-cemented prosthesis fixation with and without the use of an injectable bone substitute, using an experimental rabbit model.
Key findings outlined in the publication include:
- Improved stabilization of the prosthesis was found with CERAMENT™ in the short-term period.
- Biological reinforcement of the fixation by a gradual substitution of the bone substitute with living bone could be important for long-term fixation.
- At 12 weeks, pull-out forces were significantly higher in the CERAMENT group as compared to the no bone substitute group.
- No adverse events were observed with the CERAMENT group.
"We are encouraged by the results reported in this study," said Professor Magnus Tagil, of the Department of Orthopedics, Clinical Sciences, Lund University. "We found using CERAMENT™ to fill out the interface between the cementless prosthesis and the bone offers the potential to improve the stability of the prosthesis during the important first months."
"This study is yet another supportive data point to add to more than 45 studies reported on CERAMENT™|BONE VOID FILLER," said Lloyd Diamond, CEO of BONESUPPORT. "Studies like this provide validation to further explore opportunities for the use of CERAMENT in revision procedures."
Access the study at: http://www.josr-online.com/content/pdf/1749-799X-8-25.pdf .
Note: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
BONESUPPORT is an emerging leader of injectable bone graft substitutes for orthopedic trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENT™ is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENT's unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENT™|G is the first CE-marked injectable antibiotic eluting ceramic bone graft substitute. CERAMENT™|G is indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections) in CE marked countries. CERAMENT™|G is not available in the United States.
CERAMENT™ is a fully developed product platform that is commercially available in the U.S. and Europe and is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT spans more than eleven years. Over forty-five pre-clinical, clinical and animal studies have been conducted and more than 4,000 patients have been treated with CERAMENT. The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT please visit www.bonesupport.com.
Chief Financial Officer